BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » STEMCELL Technologies

STEMCELL Technologies Keeps Expanding – Launches New Offices and Labs in UK

January 31, 2017 By Cade Hildreth (CEO) Leave a Comment

STEMCELL Technologies UK

STEMCELL Technologies Opens New Office and Laboratories in Cambridge, UK

STEMCELL Technologies UKJanuary 31, 2017 03:30 AM EST, CAMBRIDGE, England– STEMCELL Technologies UK has recently celebrated the grand opening of their Cambridge-based facility. Founded by Dr. Allen Eaves, STEMCELL provides specialized reagents and tools that support research on cancer and other diseases, as well as cell therapy and regenerative medicine globally. Cambridge is a leading global hub for stem cell research. This, combined with its proximity to STEMCELL’s customers in the UK and Europe, makes the location a natural choice for continued investment by the company. [Read more…]

Filed Under: Stem Cells Tagged With: STEMCELL Technologies

Implications of Genomic Instability in Human Pluripotent Stem Cells

September 25, 2016 By Cade Hildreth (CEO) Leave a Comment

It has been widely reported that human pluripotent stem cells (hPSCs) can become karyotypically unstable during their prolonged culture in vitro (1-4). These cytogenetic changes bear stark similarities to those found in many human cancers raising safety concerns for their potential use in regenerative medicine. Although the mechanisms behind these changes are still to be elucidated, they have been shown to provide variant cells with a selective advantage and rapidly out-compete normal cells in culture.

Characteristics of karyotypically abnormal hPSCs include resistance to apoptosis, altered differentiation patterns and persistent stem cells populations in teratomas. As the first clinical trials using hPSC-derived cells are underway, it is imperative that we understand the implications of these changes and how to detect and minimize their occurrence in hPSC cultures.

“Safety of hPSC-derived cellular products is the first and foremost requirement for fulfillment of hPSC clinical potential,” says Dr. Ivana Barbaric, Lecturer and Principal Investigator at the Centre for Stem Cell Biology, the University of Sheffield. “Genome stability of hPSCs is of particular concern given the association of genetic changes and malignant phenotype in cancerous cells. In addition to mutational rates, the selection pressures that cells experience during the single-cell passaging may play a role in the appearance of genetically variant cells in cultures.” [Read more…]

Filed Under: Stem Cells Tagged With: genomic instability, STEMCELL Technologies

Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more

April 24, 2016 By Cade Hildreth (CEO) Leave a Comment

Breaking: STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, & more

This was a major week in the stem cell sector, with significant announcements released by STEMCELL Technologies, Accellta, Cellect Biomed, CardioCell, and more. The FDA also released significant news pertaining to a public hearing that will  address the regulation of stem cells within the United States. [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: Accellta, CardioCell, Cellect Biomed Ltd., STEMCELL Technologies

STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids
(‘Mini Brains’) for Researchers

April 15, 2016 By Cade Hildreth (CEO) Leave a Comment

STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids for Researchers

In major news released today, STEMCELL Technologies announced that it has partnered with the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria, to develop products for cerebral organoid culture for researchers worldwide.

Founded in 1993 and headquartered in Vancouver, Canada, STEMCELL Technologies is a diversified provider of stem cell research products. The company is known for utilizing strategic alliances to grow its dominance within the stem cell field. Current partnerships of STEMCELL Technologies include a licensing deal with the Wisconsin Alumni Research Foundation (WARF), iPS Academia Japan Inc., Salk Institute for Biological Sciences, and more.

To learn more, read the full press release released by STEMCELL Technologies, printed with permission from Sam Lloyd-Burton, Senior Product Marketing Manager, Neural and Pluripotent Stem Cell Biology, at STEMCELL Technologies.

[Read more…]

Filed Under: iPS Cells, Neural Stem Cells, Stem Cells Tagged With: iPSCs, neural stem cells, press release, STEMCELL Technologies

BioInformant Releases “Stem Cell Research Products – Opportunities, Tools, & Technologies” with Market Size, Segments, Trends, & Projections to 2020

February 10, 2016 By Cade Hildreth (CEO) Leave a Comment

BioInformant Releases “Stem Cell Research Products, Opportunities, Tools, & Technologies - Market Size, Segments, Trends, and Projections to 2020”

February 11, 2016; Washington, DC — BioInformant announces the February 2016 release of its global strategic report, “Stem Cell Research Products, Opportunities, Tools, and Technologies” with market size, segments, trends, and projections to 2020.

The first and only market research firm to specialize in the stem cell industry, BioInformant has more than a decade of historical information on all segments of the stem cell market, by stem cell type. This powerful 175 page global strategic report contains market size, segments, trends, and projections through 2020, as well a social analytics and an end-user survey of nearly 300 stem cell scientists. The “Survey of Stem Cell Scientists” identifies technical requirements, unmet needs, and purchasing preferences of stem cell researchers worldwide. [Read more…]

Filed Under: Adipose SCs, HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells Tagged With: market report, press release, research products, stem cells, STEMCELL Technologies, Thermo Fisher Scientific

  • 1
  • 2
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.